Lilly said the plant will strengthen its global supply chain and expand the capacity for its growing portfolio of oral ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for type 2 ...

Last week will likely be remembered as the one in which pharma frustrations with the UK boiled over. MSD's decision to pull back from a £1 billion ($1.35 billion) investment in the country was bad ...